A Lower GLP-1 Dose With PCOS (Now PMOS): Does Maintenance Dosing Actually Work?

Almost nobody arrives at this question because a doctor raised it. It comes up because the medication costs more per month than it used to, or the supply went unreliable, or the nausea never fully settled, or the weight stopped moving and staying at the top dose started to feel like paying full price for nothing.

So the question forms on its own: do I have to keep taking this much of it, forever?

Most of what's written about GLP-1s and PCOS — now PMOS, after the 2026 Lancet consensus renamed it — treats this as binary. You're on it, or you've stopped and the weight comes back. The middle option barely gets discussed, which is strange, because it's the one most people are quietly improvising already.

There is now real evidence on that middle. It's thinner than the internet suggests, it's better than nothing, and one specific part of it has almost nothing to do with PMOS.

What "a lower dose" actually means — two different things

These get blurred constantly, and they aren't the same decision.

Microdosing usually means starting below the standard 0.25 mg weekly and staying there — the approach several telehealth operators now build programs around. It's a way into the medication.

Maintenance or reduced-frequency dosing means stepping down after you've already responded — same dose stretched to every two weeks, or a smaller weekly dose, once you've reached whatever you were aiming for.

The published evidence we describe below is about the second one. When a clinic page cites "the research on microdosing," it's frequently borrowing this de-escalation data to support a starting-dose protocol the data never tested. Worth knowing which one you're reading.

The reduced-frequency evidence, stated honestly

Two papers, both in Obesity, are doing nearly all the work here.

The first, from 2025, is the source of the number you'll see repeated everywhere: switching 2.4 mg semaglutide from weekly to once every two weeks holds 72% of the weight loss while halving the doses — modeled as a drop from 17% to 12% steady-state body weight loss. Monthly dosing held roughly half.

That figure is worth trusting only as far as its method goes. It came out of a pharmacokinetic model of virtual patients. The real humans in that paper number two — a man in his 30s and a woman in her 50s, both on tirzepatide, one of them stretching doses because of supply shortages. Neither had PMOS. The authors say plainly that a larger case series is needed. It is a well-reasoned prediction, not an outcome.

The second paper, published June 2026, is the larger case series that prediction called for. Thirty people who had plateaued on weekly semaglutide or tirzepatide moved to every-other-week dosing at the same dose and were followed an average of 36.3 weeks. Weight didn't merely hold — it fell further, from 87.9 kg at baseline to 74.1 kg on weekly dosing to 72.4 kg on reduced frequency. Truncal fat declined, skeletal muscle stayed stable, and the metabolic syndrome improvements held.

The caveats are load-bearing. It's retrospective, thirty people, no control group, published in a supplement issue, and the senior author is a trial investigator for both Novo Nordisk and Eli Lilly. Thirty people who plateaued and then chose to stretch their dosing are not a random sample of anyone.

Together these support a modest claim: structured de-escalation looks promising and is worth a conversation. They do not support "tapering is proven," and you should treat any page that says otherwise as not having read the papers. We'd add one specific warning — a widely repeated claim that a Danish study showed tapering beats stopping outright does not appear to exist. We went looking in PubMed and couldn't find it.

The trial evidence points the other way, and that matters

The strongest randomized data on this question is STEP 4, in JAMA in 2021. People ran in on semaglutide for 20 weeks, then either continued weekly or switched to placebo. Those who continued kept losing. Those who switched regained.

That's a real result and it isn't friendly to the de-escalation story. But note what it compared: full dose versus nothing. It did not test a reduced dose or a stretched interval. The honest summary of the whole literature is that the well-controlled evidence covers on-versus-off, and the reduced-dose question has only case series and modeling behind it. Nobody has run the trial that would settle it.

The PMOS question nobody has measured

Here's where the general obesity literature stops being enough for you.

Every study above measures weight, body composition, and metabolic markers. For PMOS, those aren't the only endpoints that matter — and often aren't the ones you're actually tracking. Cycle regularity. Whether you're ovulating. Free testosterone and SHBG. The skin and hair changes that follow androgens rather than the scale.

The PMOS-specific GLP-1 evidence — reviewed in Endocrine Connections in 2025 — is genuinely encouraging on those endocrine and reproductive outcomes. It is also, without exception, evidence collected at standard doses. No study has asked whether ovulation that returned on a full dose persists at half the frequency, or whether androgens drift back up before weight does.

That gap cuts both ways, and we won't pretend to know which. Insulin resistance is the mechanism GLP-1s act through in PMOS, and if reduced dosing holds the metabolic gains — which is what the 2026 series suggests — there's a plausible case the hormonal ones follow. Equally plausible: reproductive endpoints are more dose-sensitive than weight, and the scale stays flat while the cycle quietly slips. Both are hypotheses. Neither has been tested.

The practical consequence is that the scale is the wrong instrument for this decision. If you step down, weight is the variable most likely to look fine and least likely to tell you what's happening underneath.

How to have this conversation

Track the PMOS outcomes, not just the weight. Cycle length and ovulation signs are the readouts that would actually detect a problem, and they need a baseline from before you change anything — a few months of data, not a memory.

Give it long enough to mean something. The 2026 series ran an average of 36.3 weeks. Six weeks of feeling fine says very little.

Bring the real reason. Cost, side effects, plateau, and stopping in order to conceive are four different problems, and the last one has specific guidance attached that the others don't. GLP-1s are prescribed off-label for PMOS nearly everywhere, and every regimen described in this article is off-label on top of that — which makes your prescriber more necessary to the plan, not less.

And it's worth knowing which version of PMOS you're working with before you change the dose. Insulin-driven presentations are the ones GLP-1s target most directly; androgen-dominant and ovulation-driven presentations don't necessarily track the same way on the way down. Our free assessment reads your symptom pattern and points to the driver most likely behind yours in about five minutes — no labs, and it won't diagnose you, but it tells you which markers are worth watching if you step down. If the metabolic side is the piece you're trying to hold onto, the metformin and inositol comparison covers what else acts on that pathway, and our read of the 2026 GLP-1 evidence has the full-dose picture.

---

We inform; we don't diagnose or prescribe. Semaglutide and tirzepatide are prescription medications — starting, stopping, or changing the dose or interval of either is a decision for you and your clinician.

Sources

• Wu CC, Cengiz A, Lawley SD. Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy. Obesity (Silver Spring), 2025 Jul;33(7):1232–1236. PMID: 40415172. DOI: 10.1002/oby.24302
• Wong M, et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity (Silver Spring), 2026 Jun. PMID: 41732031
• Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021 Apr 13;325(14):1414–1425. PMID: 33755728
• Monney M, Mavromati M, Leboulleux S, Gariani K. Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review. Endocrine Connections, 2025 May 1;14(5):e240529. PMID: 40066975. DOI: 10.1530/EC-24-0529
• Teede HJ, et al. 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Monash University / international consensus, 2023.